

Hypertensive disorders of pregnancy and risk of cardiovascular disease: A Mendelian Randomisation study in the UK Biobank

Lena Tschiderer, PhD,^{1,2} Yvonne T van der Schouw, PhD,² Stephen Burgess, PhD,^{3,4,5} Kitty WM Bloemenkamp, PhD,⁶ Lisa Seekircher, PhD,¹ Peter Willeit, PhD,^{1,3} N Charlotte Onland-Moret, PhD,² Sanne AE Peters, PhD^{2,7,8}

¹Institute of Health Economics, Medical University of Innsbruck, Innsbruck, Austria;

²Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands;

³Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom;

⁴Heart and Lung Research Institute, University of Cambridge, Cambridge, United Kingdom;

⁵MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom;

⁶Department of Obstetrics, Division Women and Baby, Birth Centre Wilhelmina Children Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands;

⁷The George Institute for Global Health, School of Public Health, Imperial College London, London, United Kingdom;

⁸The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.

Short title: Hypertensive disorders of pregnancy & CVD risk

Correspondence to:

Sanne AE Peters

Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands

Utrecht, Utrecht, the Netherlands

Phone: +31887568181

E-mail: S.A.E.Peters@umcutrecht.nl

Word count: 5,992; 1 Table; 4 Figures

1 **Abstract**

2 **Background:** Observational studies show that hypertensive disorders of pregnancy
3 (HDPs) are related to unfavourable maternal cardiovascular disease (CVD) risk
4 profiles later in life. We investigated whether genetic liability to pre-
5 eclampsia/eclampsia and gestational hypertension is associated with CVD risk
6 factors and occurrence of CVD events.

7 **Methods:** We obtained genetic associations with HDPs from a genome-wide
8 association study and used individual-participant-data of women and men from the
9 UK Biobank to obtain genetic associations with CVD risk factors and CVD events
10 (defined as myocardial infarction or stroke). The rationale for including men and
11 nulligravidae was to study genetic liability to HDPs and CVD risk without
12 experiencing the underlying phenotype. We applied Mendelian Randomisation
13 analysis using inverse variance weighted regression in our primary analysis.

14 **Results:** We included 264,160 women (mean age 56.4 [SD 8.0]) and 223,043 men
15 (mean age 56.7 [8.2]) with available genetic data. Genetically proxied pre-
16 eclampsia/eclampsia was related to higher risk of CVD with odds ratios of 1.20 (1.01,
17 1.43) and 1.29 (1.08, 1.53) in women and men, respectively. For genetically proxied
18 gestational hypertension, odds ratios for CVD were 1.22 (1.10, 1.36) and 1.28 (1.16,
19 1.42) in women and men, respectively. Furthermore, genetically proxied HDPs were
20 associated with higher levels of systolic and diastolic blood pressure and younger
21 age at hypertension diagnosis in both women and men.

22 **Conclusions:** Genetic liability to HDPs including pre-eclampsia/eclampsia and
23 gestational hypertension is associated with higher CVD risk, implying biological
24 mechanisms relating to these disorders are causally related to CVD risk in both
25 women and men.

26 Introduction

27 Hypertensive disorders of pregnancy (HDPs) affected one in eight hospital deliveries
28 in 2019 and came along with one in four maternal deaths between 2017 and 2019 in
29 the US.¹ Globally, there were 18.1 million incident cases of hypertensive pregnancy
30 disorders in 2019.² They can express as different phenotypes including gestational
31 hypertension, pre-eclampsia/eclampsia, and HELLP syndrome. Pre-eclampsia is a
32 multi-organ disease originating from a dysfunction of the placenta and affects
33 approximately one in twenty deliveries.^{3,4} The International Society for the Study of
34 Hypertension in Pregnancy defines pre-eclampsia as gestational hypertension with
35 one or more of the following concomitants: (1) proteinuria, (2) other maternal organ
36 dysfunction (acute kidney injury, liver involvement, neurological or haematological
37 complications), or (3) uteroplacental dysfunction.⁵ Eclampsia is a progression of pre-
38 eclampsia, in which women additionally experience seizures.⁶ Gestational
39 hypertension is defined as *de novo* hypertension at ≥ 20 weeks of gestation without
40 the additional signs of pre-eclampsia.⁵

41 A range of risk factors for HDPs have been proposed including higher pre-pregnancy
42 body mass index (BMI), pre-pregnancy diabetes mellitus, chronic hypertension,
43 chronic autoimmune disease, and maternal age.^{7,8} Furthermore, HDPs are related to
44 multiple immediate, short-term, and long-term health concerns, which can affect the
45 mother and the foetus and neonate.⁹ Short-term outcomes are, for instance, stillbirth
46 and preterm delivery,⁹ whereas on the long term HDPs are associated with maternal
47 cardiovascular risk factors after pregnancy including diabetes mellitus,
48 hyperlipidaemia, and hypertension.⁹ Observational studies have also reported a
49 relation between HDPs and higher risk of maternal cardiovascular disease (CVD)
50 events later in life,⁹ which has been confirmed in co-sibling analyses¹⁰ and by a
51 previous Mendelian Randomisation (MR) study that was restricted to sex-combined
52 genetic associations with CVD events.¹¹

53 However, the specific biological mechanisms behind HDPs and CVD risk are not
54 entirely clear. As HDPs and CVD share a considerable amount of risk factors, the
55 theory emerged that both phenotypes are expressions of the same disease pathway
56 at different stages in life,¹² and that pregnancy enables earlier identification of

57 women at higher CVD risk.¹³ Apart from that, HDPs could also cause long-term
58 vascular damage leading to a higher CVD risk later in life.¹³

59 To better understand the role of HDPs in the development of CVD, we conducted a
60 MR analysis of 487,203 women and men from the UK Biobank with the aim to
61 estimate the sex-specific relation of genetic liability to pre-eclampsia/eclampsia and
62 gestational hypertension with CVD events, blood pressure-traits, and lipid-, liver-,
63 and kidney-related cardiovascular risk factors. The rationale for also analysing men
64 and nulligravidae was to study the role of genetic liability to HDPs in cardiovascular
65 risk without experiencing the underlying phenotype, which could help understand
66 whether biological mechanisms related to HDPs or the diseases themselves are
67 responsible for higher CVD risk.

68 **Methods**

69 This analysis adheres to the STROBE-MR statement (**Table S1**).¹⁴ Please see the
70 Major Resources Table in the Supplemental Materials.

71 **Study design and data sources**

72 The present study included data from the UK Biobank, of which details have been
73 described previously.¹⁵ Briefly, the UK Biobank is a large-scale prospective study in
74 the general population of the UK, in which over 500,000 individuals aged 40 to 69
75 years were recruited between 2006 and 2010.¹⁵ The UK Biobank was approved by
76 the North-West Multi-Centre Research Ethics Committee and all participants
77 provided written informed consent.

78 For the MR analysis, we used individual-level imputed data on genetic variants.
79 Genotyping was performed using the Affymetrix UK BiLEVE Axiom array and the
80 Affymetrix UK Biobank Axiom Array.^{16,17} Genotype imputation was based on the
81 Haplotype Reference Consortium and the UK10K haplotype reference panel.¹⁸

82 Of the 502,412 UK Biobank participants, we excluded 15,209 individuals because
83 they had missing values on the genetic variants included in our analysis. The
84 remaining 487,203 individuals contributed to the present analysis.

85 Specific definitions of pre-eclampsia/eclampsia, gestational hypertension, CVD
86 events, and additional variables are outlined in **Supplementary Methods**.

87 **Statistical analysis**

88 We summarised continuous variables with mean and standard deviation (SD), if
89 normally distributed, and with median and interquartile range, otherwise. Categorical
90 variables were summarised with number and percentage. For all analyses, we used
91 two-sided statistical tests and deemed $P\text{-values} \leq 0.05$ as statistically significant.
92 Analyses were carried out using R 4.0.5 (The R Foundation, Vienna, Austria).

93 **Instrumental variable**

94 For our instrumental variables, we used SNPs for pre-eclampsia/eclampsia and
95 gestational hypertension identified by a recent genome-wide association study
96 (GWAS) by Honigberg et al.¹⁹ We used effect sizes and standard errors from the
97 discovery analysis, which excluded data from the UK Biobank, allowing two-sample
98 MR.¹⁹

99 As illustrated in **Figure S1**, twelve SNPs for pre-eclampsia/eclampsia and seven
100 SNPs for gestational hypertension were identified by the GWAS.¹⁹ We harmonised
101 the summary-level data to be represented on the same strand. Furthermore, we
102 excluded palindromic SNPs with allele frequencies between 0.45 and 0.55. For both
103 exposures, we excluded one palindromic SNP (rs9855086). To identify related traits,
104 we scanned Phenoscanner²⁰ (on February 14th 2023) and extracted all traits
105 associated with the SNPs or any proxies in high linkage disequilibrium ($R^2 \geq 0.8$) with
106 $P\text{-values} \leq 5 \times 10^{-8}$ omitting traits identified from the UK Biobank by Neale et al.
107 (<http://www.nealelab.is/uk-biobank/>). Details on the SNPs included in the present
108 analysis and related traits are provided in **Table S2**.

109 We measured the strength of our instrumental variable based on the F-statistics of
110 each SNP individually, which ranged from 30 to 58.

111 **Primary analysis**

112 We conducted all analyses sex-specific and for women and men combined. For the
113 association between the genetic variants and CVD events, we implemented logistic
114 regression adjusting for age at baseline, sex, if appropriate, and the first 16 genetic
115 principal components, as suggested previously.²¹ We conducted the MR analysis

116 using the R-package *MendelianRandomization*.²² In the primary analysis, we applied
117 inverse variance weighted (IVW) regression. We obtained women-to-men ratios of
118 odds ratios (ORs) and 95% confidence intervals (CIs) by subtracting logORs for men
119 from logORs for women and adding sex-specific variances. All ORs in MR analyses
120 are reported per unit increase in the log odds of genetically proxied pre-
121 eclampsia/eclampsia and gestational hypertension.

122 **Sensitivity analyses**

123 Sensitivity analyses were conducted similarly to the primary analysis but by applying
124 simple and weighted median regression, MR-Egger, and MR-PRESSO.²³

125 Furthermore, we studied associations between genetic variants and CVD events
126 using a Cox proportional hazards model. We used age as underlying timescale and
127 adjusted for sex, if appropriate, and the first 16 genetic principal components. For
128 this sensitivity analysis we excluded all individuals with history of CVD (defined as
129 myocardial infarction or stroke) at baseline. Time-to-event was defined as time to the
130 first CVD event, death, or end of follow-up, whichever occurred first.

131 Moreover, we conducted a sensitivity analysis, classifying women into ever and
132 never pregnant. We obtained ever-to-never-pregnant ratios of ORs and 95% CIs by
133 subtracting logORs for never pregnant from logORs for ever pregnant women and
134 adding corresponding variances.

135 **Secondary analyses**

136 In addition, we conducted a MR analysis using a set of cardiovascular risk factors as
137 outcome variables. We analysed blood pressure-related traits including systolic
138 blood pressure (SBP), diastolic blood pressure (DBP), and age at hypertension
139 diagnosis. Furthermore, we analysed additional CVD risk factors including BMI, total
140 cholesterol, high-density lipoprotein cholesterol, triglycerides, low-density lipoprotein
141 cholesterol, lipoprotein(a), apolipoprotein A1, apolipoprotein B, HbA1c, creatinine,
142 albumin, ALAT, ASAT, GGT, and C-reactive protein. For obtaining genetic
143 associations with risk factors, we used linear regression analysis adjusting for age,
144 sex, if appropriate, and the first 16 genetic principal components,²¹ and divided all
145 cardiovascular risk factors by their SD to enhance the comparison between the
146 individual risk factors. The MR analysis was based on IVW regression.

147 **Results**

148 **Characteristics of the study population**

149 Baseline characteristics of the included participants are outlined in **Table 1**. The
150 present analysis included 264,160 (54%) women and 223,043 (46%) men. Mean age
151 at baseline was 56.5 (SD 8.1) years. CVD was reported in 13,861 women (7,232
152 myocardial infarctions; 7,436 strokes) and 27,682 men (19,746 myocardial
153 infarctions; 10,104 strokes).

154 **MR analysis of genetically proxied HDPs and risk of CVD**

155 **Primary analysis**

156 As depicted in **Figure 1**, in women and men, respectively, genetically proxied pre-
157 eclampsia/eclampsia was related to a higher risk of CVD with ORs of 1.20 (95% CI
158 1.01, 1.43) and 1.29 (1.08, 1.53) and to a higher risk of ischaemic CVD with ORs of
159 1.24 (1.02, 1.52) and 1.32 (1.10, 1.59). We found no significant association with risk
160 of haemorrhagic stroke. Women-to-men ratios of ORs revealed no differences
161 between sexes.

162 **Figure 2** shows the MR analyses for gestational hypertension and CVD events. In
163 women and men, respectively, ORs were 1.22 (1.10, 1.36) and 1.28 (1.16, 1.42) for
164 CVD and 1.22 (1.10, 1.37) and 1.32 (1.19, 1.47) for ischaemic CVD. ORs for
165 haemorrhagic stroke were 1.37 (1.07, 1.77) and 1.12 (0.72, 1.75) in women and
166 men, respectively. Again, women-to-men ratios of ORs were not statistically
167 significantly different from one.

168 In sex-combined analyses both genetically proxied HDPs were related to a higher
169 risk of CVD, ischaemic CVD, myocardial infarction, stroke, and ischaemic stroke, but
170 not with haemorrhagic stroke and intracerebral haemorrhage (**Figure S2** and **Figure**
171 **S3**). Genetically proxied gestational hypertension but not pre-eclampsia/eclampsia
172 was associated with higher risk of subarachnoid haemorrhage.

173 **Sensitivity analyses**

174 In sensitivity analyses, applying simple and weighted median regression, results
175 were broadly similar when investigating genetically proxied pre-eclampsia/eclampsia
176 in women (**Figure S4**), men (**Figure S5**), and women and men combined (**Figure**

177 **S6**). When applying MR-Egger, the OR for intracerebral haemorrhage was 6.21
178 (1.16, 33.31) in the sex-combined analysis with indication of directional pleiotropy (P-
179 value intercept=0.027). ORs from MR-Egger regression for all other cardiovascular
180 events were not statistically significant. **Table S3** shows the results of MR-PRESSO,
181 which detected outlying variants in the analysis of women, men, and in the sex-
182 combined analysis. The effect sizes remained similar but the association between
183 genetically proxied pre-eclampsia/eclampsia and higher risk of myocardial infarction
184 in women became statistically significant.

185 When analysing genetically proxied gestational hypertension, results remained
186 robust when implementing simple or median weighted regression for the analysis in
187 women (**Figure S7**), in men (**Figure S8**), and in sex-combined analyses (**Figure S9**).
188 In women, MR-Egger regression yielded a statistically significant intercept (P-
189 value=0.002) when analysing the combined stroke endpoint (**Figure S7**). **Table S3**
190 shows the results of MR-PRESSO, in which genetically proxied gestational
191 hypertension was statistically significantly related to a higher risk of haemorrhagic
192 stroke in the sex-combined analysis (OR 1.32 [1.22, 1.44]).

193 The Cox regression analysis included 258,416 women and 209,387 men without a
194 history of CVD at baseline. As depicted in **Figure S10**, results remained broadly
195 similar compared to the primary analysis. Genetically proxied pre-
196 eclampsia/eclampsia was related to hazard ratios of 1.13 (0.95, 1.34) and 1.20 (1.01,
197 1.44) for CVD in women and men, respectively, with no significant differences
198 between the sexes. Hazard ratios for CVD were 1.17 (1.03, 1.32) in women and 1.25
199 (1.13, 1.38) in men, when analysing genetically proxied gestational hypertension
200 (**Figure S11**). Results of the sex-combined analysis are provided in **Figure S12** and
201 **Figure S13** and were also comparable to the findings of the primary analysis.

202 **Figure S14** and **Figure S15** show the MR analyses by history of pregnancy. The
203 excess risk for ischaemic stroke for genetic liability to gestational hypertension was
204 higher in ever compared to never pregnant women with a ratio of ORs of 1.84 (1.04,
205 3.24). We found no significant differences when analysing pre-eclampsia/eclampsia
206 and gestational hypertension and other CVD events.

207 **MR analysis of genetically proxied HDPs with blood pressure-traits** 208 **and cardiovascular risk factors**

209 **Figure 3** shows the associations between genetically proxied pre-
210 eclampsia/eclampsia and a range of cardiovascular risk factors. Genetically proxied
211 pre-eclampsia/eclampsia was related to higher levels of SBP and DBP and younger
212 age at hypertension diagnosis. Furthermore, we found a significant association with
213 lower levels of total cholesterol in both women and men. There were no sex-
214 differences in any of the associations.

215 Relations between genetically proxied gestational hypertension and cardiovascular
216 risk factors are depicted in **Figure 4**. Genetically proxied gestational hypertension
217 was associated with higher levels of SBP and DBP and younger age at hypertension
218 diagnosis in women and men with no statistically significant differences between
219 women and men.

220 Sex-combined analyses for genetically proxied pre-eclampsia/eclampsia and
221 gestational hypertension are shown in **Figure S16** and **Figure S17**, respectively.
222 Again, both genetically proxied pre-eclampsia/eclampsia and gestational
223 hypertension were related to higher levels of SBP and DBP and younger age at
224 hypertension diagnosis. Additionally, genetically proxied pre-eclampsia/eclampsia
225 was associated with lower levels of several lipid parameters.

226 **Discussion**

227 In this analysis, we found associations between genetic liability to pre-
228 eclampsia/eclampsia and gestational hypertension and higher risk of CVD in both
229 women and men. Furthermore, both HDPs were related to higher levels of SBP and
230 DBP and younger age at hypertension diagnosis.

231 **Findings from previous studies**

232 A positive association between HDPs and risk of CVD has previously been reported
233 by observational studies. A large-scale meta-analysis showed that moderate and
234 severe pre-eclampsia are associated with a higher risk of maternal CVD, with ORs of
235 2.24 (1.72, 2.93) and 2.74 (2.48, 3.04), respectively.²⁴ The same is the case for

236 gestational hypertension, for which an OR for maternal CVD of 1.67 (1.28, 2.19) has
237 been reported.²⁴ Moreover, a phenome-wide association analysis showed strong
238 associations between polygenic risk scores of HDPs with CVD risk factors (such as
239 hypertension, diabetes mellitus, hyperlipidaemia, and obesity) and CVD events
240 (including ischaemic heart disease and coronary atherosclerosis) in women and
241 men.¹⁹ In addition, a recent MR analysis, which only included women for genetic
242 associations with HDPs, showed genetically proxied HDPs to be related to a higher
243 risk of coronary artery disease or ischaemic stroke.¹¹ Furthermore, genetically
244 proxied pre-eclampsia and gestational hypertension were associated with a higher
245 risk of coronary artery disease but not with risk of ischaemic stroke.¹¹ This is not in
246 line with the results of the present study, in which we did find a significantly higher
247 risk for ischaemic stroke for genetically proxied pre-eclampsia/eclampsia in women.
248 However, it has to be noted that the previous MR study only included data from one
249 database for obtaining genetic associations with genetically proxied HDPs and used
250 sex-combined effect sizes for the genetic associations with CVD events, which could
251 potentially explain these differences.¹¹ In the present MR study, we (1) used effect
252 sizes for the genetic association with the exposure from a large-scale GWAS that
253 meta-analysed results of multiple studies, (2) analysed sex-specific effect sizes for
254 the genetic association with the outcome, (3) included analyses restricted to men,
255 and (4) studied associations with blood pressure-, lipid-, liver-, and kidney-related
256 traits.

257 **HDPs and blood pressure**

258 Per definition, hypertension is the major component of HDPs. In the present
259 analysis, we showed that genetically proxied pre-eclampsia/eclampsia and
260 gestational hypertension are significantly associated with both higher SBP and DBP
261 later in life. Genetic correlation between HDPs and blood pressure has previously
262 been demonstrated.¹⁹ Notably, the genetic correlation between gestational
263 hypertension and SBP was even higher than between SBP and DBP.¹⁹ A previous
264 MR analysis showed that higher genetically predicted SBP was also related to an
265 elevated risk for pre-eclampsia/eclampsia.²⁵ Moreover, higher levels of genetically
266 proxied blood pressure have been related to an increased risk of CVD in both
267 women and men.²⁶ In case blood pressure lies on the causal pathway between pre-
268 eclampsia/eclampsia and gestational hypertension and CVD, we speak of vertical

269 pleiotropy, which does not bias the findings of our MR analysis. However, we cannot
270 fully exclude horizontal pleiotropy, which would violate the assumptions of MR. When
271 applying MR-Egger, we found no significant intercepts in the relation of pre-
272 eclampsia/eclampsia and CVD, which indicates absence of directional pleiotropy.
273 We did find a significant MR-Egger intercept in the association between genetically
274 proxied gestational hypertension and risk of stroke and ischaemic stroke in women.
275 However, it has previously been discussed that MR-Egger results can be influenced
276 by outlying variants.²⁷ When we further studied the relation between genetically
277 proxied gestational hypertension and risk of stroke and ischaemic stroke applying
278 MR-PRESSO, the findings of our primary analysis remained robust.

279 **Differences between ischaemic and haemorrhagic events**

280 Our MR analysis revealed both pre-eclampsia/eclampsia and gestational
281 hypertension to be related to ischaemic CVD. Contrarily, we found no statistically
282 significant association between pre-eclampsia/eclampsia and risk of haemorrhagic
283 stroke. These findings are not in line with results from previous observational
284 studies. In a US database it has been shown that pre-eclampsia/eclampsia was
285 associated with an OR for pregnancy-related intracerebral haemorrhage of 10.39
286 (8.32, 12.98).²⁸ Moreover, a study from Taiwan reported a hazard ratio for
287 haemorrhagic stroke of 3.50 (2.31, 5.29) related to pre-eclampsia.²⁹ Another analysis
288 in Canadian women found pre-eclampsia to be related to a higher risk of
289 haemorrhagic stroke.³⁰ Therefore, our findings suggest that the results of
290 observational studies may be biased by potential confounding factors affecting the
291 relation between pre-eclampsia/eclampsia and risk of haemorrhagic stroke.
292 However, especially our sex-specific analysis may have limited statistical power to
293 analyse haemorrhagic stroke events, which could have prevented us from finding
294 statistically significant associations. Nevertheless, in sex-combined analyses, we
295 also did not find significant association of genetically proxied pre-
296 eclampsia/eclampsia and occurrence of haemorrhagic stroke. In contrast, we did find
297 a statistically significant association between genetically proxied gestational
298 hypertension and the risk of subarachnoid haemorrhage in our sex-combined
299 analysis. This indicates potential differences between the roles of pre-
300 eclampsia/eclampsia and gestational hypertension in the risk for haemorrhagic
301 stroke.

302 **HDPs in men and nulligravidae**

303 Our MR analysis also included men and nulligravidae, who can have the genetic
304 liability to HDPs although the underlying phenotype can never express.
305 Nevertheless, we found genetic liability to pre-eclampsia/eclampsia and gestational
306 hypertension to be related to a higher risk of CVD events in men. Robillard et al.
307 previously suggested the importance paternity in the development of pre-eclampsia
308 and reported a significantly higher risk for pre-eclampsia in new paternity multiparas
309 compared to same paternity multiparas and primiparas.³¹ To further investigate how
310 the genetic liability to HDPs expresses in men, we studied their relationship with a
311 range of cardiovascular risk factors. Interestingly, genetically proxied HDPs were
312 also related to younger age at hypertension diagnosis in men. A recently conducted
313 phenome-wide association study investigated the relation between polygenic risk
314 scores for pre-eclampsia/eclampsia and gestational hypertension with >1,000
315 phenotypes in men and also reported hypertension to be one of the key associated
316 characteristics.¹⁹ This is indicative that earlier hypertension is a main driver of the
317 underlying mechanisms leading to a higher CVD risk in males. We also analysed the
318 genetic liability to HDPs and CVD in nulligravidae. Relations were similar in never
319 and ever pregnant women for all CVD events, but ischaemic stroke, as we found a
320 statistically significantly higher excess risk for ischaemic stroke related to the genetic
321 liability to gestational hypertension for ever compared to never pregnant women.
322 However, it should be noted that statistical power for the analysis of nulligravid
323 women was limited. Consequently, the role of genetic liability to HDPs in CVD risk in
324 nulligravidae needs further investigation.

325 **Strengths and limitations**

326 Our study has several strengths. We used data from UK Biobank, which provided
327 adequate statistical power to conduct the MR analyses. Furthermore, we built our
328 genetic instruments on a comprehensive large-scale GWAS that meta-analysed data
329 from multiple studies.¹⁹ Moreover, due to the use of individual-participant data from
330 the UK Biobank, we were able to study sex-specific associations of genetic variants
331 with CVD events. In addition, we conducted several sensitivity analyses including
332 different methods of MR and a Cox-regression analysis based on time-to-event data.
333 Our analysis also has limitations. First, the effect sizes for the genetic association

334 with the exposure variable were based on individuals of different ancestries, while
335 the UK Biobank majorly includes individuals of European ancestry. Furthermore, we
336 did not have adequate statistical power for analysing nulligravid women, limiting the
337 interpretation of our findings. Moreover, MR analysis relies on three assumptions.
338 The first assumption is that the instrumental variable is associated with the exposure.
339 Phenotypic data on pre-eclampsia/eclampsia and gestational hypertension were not
340 available in our dataset. Consequently, we were not able to investigate whether the
341 genetic instruments correlated with the phenotype in our study. However, we
342 calculated F-statistics for each SNP individually and all of them were ≥ 30 indicating
343 that we have sufficiently strong instruments. In addition, these SNPs were obtained
344 from an independent GWAS, which replicated the majority of associations in
345 additional cohorts, supporting our assumption of having robust associations with the
346 exposures. The second assumption is that the genetic instrument is not associated
347 to any confounding factor. We studied the association of genetically proxied pre-
348 eclampsia/eclampsia and gestational hypertension with several cardiovascular risk
349 factors. We found significant associations between genetically predicted HDPs and
350 lower levels of lipid parameters. As lower levels of some lipid parameters (e.g., total
351 cholesterol) are known to be related to a lower cardiovascular risk,³² while others
352 have been related to a higher cardiovascular risk (e.g., high-density lipoprotein
353 cholesterol),³³ the specific role of lipid levels on the pathway between HDPs and risk
354 of cardiovascular events needs to be further investigated. The third assumption is
355 that the genetic instrument can influence the outcome only via the exposure. To
356 study this assumption, we conducted MR-Egger regression and MR-PRESSO, which
357 indicated potential directional pleiotropy for single CVD events as discussed in detail
358 above.

359 **Conclusion**

360 Genetic liability to HDPs including pre-eclampsia/eclampsia and gestational
361 hypertension is associated with higher CVD risk, implying biological mechanisms
362 relating to these disorders are causally related to CVD risk in both women and men.

363 **Perspectives**

364 This MR study demonstrated that genetic liability to pre-eclampsia/eclampsia and
365 gestational hypertension is related to a higher risk for CVD. Additionally, genetic
366 liability to HDPs was related to higher blood pressure levels and younger age at
367 hypertension diagnosis. The findings were similar in women and men. This implies
368 that biological mechanisms related to HDPs are causally related to CVD risk.
369 Furthermore, it suggests that both HDPs and CVD events may be expressions of the
370 same disease pathway at different stages in life and that HDPs may be an indicator
371 for individuals at higher CVD risk later in life. While pregnancy allows identification of
372 women at increased risk for future CVD, men and nulligravidae with the same
373 genetic liability to HDPs may not have the opportunity to present at an earlier stage
374 in life.

375 **Acknowledgements**

376 This research has been conducted using the UK Biobank Resource (Application
377 Number 29916). We are extremely grateful to all participants in the UK Biobank.

378 **Sources of Funding**

379 This work was funded by the Austrian Science Fund (T 1253). SAEP is supported by
380 a VIDJ Fellowship from the Dutch Organisation for Health Research and
381 Development (ZonMw) (09150172010050).

382 **Disclosures**

383 None.

384 **Data availability**

385 Summary-level data from the GWAS have been published previously.¹⁹ Data from
386 the UK Biobank can be requested via their website
387 (<https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access>).

388 **Novelty and Relevance**

389 **What is New?**

- 390 • This Mendelian Randomisation study investigated the relation between
391 genetically predicted hypertensive disorders of pregnancy and the risk of
392 developing cardiovascular disease and several cardiovascular risk factors.

393 **What is Relevant?**

- 394 • The study found genetic liability to pre-eclampsia/eclampsia and gestational
395 hypertension to be linked to a higher risk of cardiovascular disease events in
396 both women and men.
- 397 • Earlier hypertension appears to be a main driver behind the relation of
398 hypertensive disorders of pregnancy and increased cardiovascular risk.

399 **Clinical/Pathophysiological implications?**

- 400 • Hypertensive disorders of pregnancy seem to be an indicator for individuals at
401 higher cardiovascular disease risk later in life.

402

403 **References**

- 404 1. Ford ND, Cox S, Ko JY, Ouyang L, Romero L, Colarusso T, Ferre CD,
405 Kroelinger CD, Hayes DK, Barfield WD. Hypertensive Disorders in Pregnancy
406 and Mortality at Delivery Hospitalization - United States, 2017-2019. *MMWR*
407 *Morb Mortal Wkly Rep.* 2022;71:585–591. doi: 10.15585/mmwr.mm7117a1.
- 408 2. Global burden of 369 diseases and injuries in 204 countries and territories,
409 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
410 *Lancet.* 2020;396:1204–1222. doi: 10.1016/S0140-6736(20)30925-9.
- 411 3. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates
412 of preeclampsia and eclampsia: a systematic review. *Eur J Obstet Gynecol*
413 *Reprod Biol.* 2013;170:1–7. doi: 10.1016/j.ejogrb.2013.05.005.
- 414 4. Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. *Lancet.*
415 2021;398:341–354. doi: 10.1016/S0140-6736(20)32335-7.
- 416 5. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall
417 DR, Warren CE, Adoyi G, Ishaku S. Hypertensive Disorders of Pregnancy:
418 ISSHP Classification, Diagnosis, and Management Recommendations for
419 International Practice. *Hypertension.* 2018;72:24–43. doi:
420 10.1161/HYPERTENSIONAHA.117.10803.
- 421 6. National High Blood Pressure Education Program Working Group on High Blood
422 Pressure. Report of the National High Blood Pressure Education Program
423 Working Group on High Blood Pressure in Pregnancy. *American Journal of*
424 *Obstetrics and Gynecology.* 2000;183:s1-s22. doi: 10.1067/mob.2000.107928.
- 425 7. Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy:
426 prevalence, risk factors, predictors and prognosis. *Hypertens Res.* 2017;40:213–
427 220. doi: 10.1038/hr.2016.126.
- 428 8. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking:
429 systematic review of controlled studies. *BMJ.* 2005;330:565. doi:
430 10.1136/bmj.38380.674340.E0.
- 431 9. Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S,
432 Magee LA, Rana S, Vermunt JV, August P. Hypertension in Pregnancy:
433 Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement
434 From the American Heart Association. *Hypertension.* 2022;79:e21-e41. doi:
435 10.1161/HYP.0000000000000208.

- 436 10. Crump C, Sundquist J, McLaughlin MA, Dolan SM, Govindarajulu U, Sieh W,
437 Sundquist K. Adverse pregnancy outcomes and long term risk of ischemic heart
438 disease in mothers: national cohort and co-sibling study. *BMJ*.
439 2023;380:e072112. doi: 10.1136/bmj-2022-072112.
- 440 11. Rayes B, Ardissino M, Slob EAW, Patel KHK, Girling J, Ng FS. Association of
441 Hypertensive Disorders of Pregnancy With Future Cardiovascular Disease.
442 *JAMA Netw Open*. 2023;6:e230034. doi: 10.1001/jamanetworkopen.2023.0034.
- 443 12. Ying W, Catov JM, Ouyang P. Hypertensive Disorders of Pregnancy and Future
444 Maternal Cardiovascular Risk. *J Am Heart Assoc*. 2018;7:e009382. doi:
445 10.1161/JAHA.118.009382.
- 446 13. O'Kelly AC, Michos ED, Shufelt CL, Vermunt JV, Minissian MB, Quesada O,
447 Smith GN, Rich-Edwards JW, Garovic VD, El Khoudary SR, et al. Pregnancy
448 and Reproductive Risk Factors for Cardiovascular Disease in Women. *Circ Res*.
449 2022;130:652–672. doi: 10.1161/CIRCRESAHA.121.319895.
- 450 14. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM,
451 Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, et al.
452 Strengthening the Reporting of Observational Studies in Epidemiology Using
453 Mendelian Randomization: The STROBE-MR Statement. *JAMA*.
454 2021;326:1614–1621. doi: 10.1001/jama.2021.18236.
- 455 15. Allen N, Sudlow C, Downey P, Peakman T, Danesh J, Elliott P, Gallacher J,
456 Green J, Matthews P, Pell J, et al. UK Biobank: Current status and what it
457 means for epidemiology. *Health Policy and Technology*. 2012;1:123–126. doi:
458 10.1016/j.hlpt.2012.07.003.
- 459 16. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott
460 P, Green J, Landray M, et al. UK biobank: an open access resource for
461 identifying the causes of a wide range of complex diseases of middle and old
462 age. *PLoS Med*. 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779.
- 463 17. Collins R. What makes UK Biobank special? *Lancet*. 2012;379:1173–1174. doi:
464 10.1016/S0140-6736(12)60404-8.
- 465 18. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A,
466 Vukcevic D, Delaneau O, O'Connell J, et al. Genome-wide genetic data on
467 ~500,000 UK Biobank participants. 2017. doi: 10.1101/166298.
- 468 19. Honigberg MC, Truong B, Khan RR, Xiao B, Bhatta L, Vy TH, Guerrero RF,
469 Schuermans A, Selvaraj MS, Patel AP, et al. Genome-wide meta-analysis

- 470 identifies novel maternal risk variants and enables polygenic prediction of
471 preeclampsia and gestational hypertension. 2022. doi:
472 10.1101/2022.11.30.22282929.
- 473 20. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J,
474 Butterworth AS, Staley JR. PhenoScanner V2: an expanded tool for searching
475 human genotype-phenotype associations. *Bioinformatics*. 2019;35:4851–4853.
476 doi: 10.1093/bioinformatics/btz469.
- 477 21. Privé F, Luu K, Blum MGB, McGrath JJ, Vilhjálmsón BJ. Efficient toolkit
478 implementing best practices for principal component analysis of population
479 genetic data. *Bioinformatics*. 2020;36:4449–4457. doi:
480 10.1093/bioinformatics/btaa520.
- 481 22. Yavorska OO, Burgess S. MendelianRandomization: an R package for
482 performing Mendelian randomization analyses using summarized data. *Int J*
483 *Epidemiol*. 2017;46:1734–1739. doi: 10.1093/ije/dyx034.
- 484 23. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal
485 pleiotropy in causal relationships inferred from Mendelian randomization
486 between complex traits and diseases. *Nat Genet*. 2018;50:693–698. doi:
487 10.1038/s41588-018-0099-7.
- 488 24. Grandi SM, Filion KB, Yoon S, Ayele HT, Doyle CM, Hutcheon JA, Smith GN,
489 Gore GC, Ray JG, Nerenberg K, et al. Cardiovascular Disease-Related
490 Morbidity and Mortality in Women With a History of Pregnancy Complications.
491 *Circulation*. 2019;139:1069–1079. doi:
492 10.1161/CIRCULATIONAHA.118.036748.
- 493 25. Ardissino M, Slob EAW, Millar O, Reddy RK, Lazzari L, Patel KHK, Ryan D,
494 Johnson MR, Gill D, Ng FS. Maternal Hypertension Increases Risk of
495 Preeclampsia and Low Fetal Birthweight: Genetic Evidence From a Mendelian
496 Randomization Study. *Hypertension*. 2022;79:588–598. doi:
497 10.1161/HYPERTENSIONAHA.121.18617.
- 498 26. Malik R, Georgakis MK, Vujkovic M, Damrauer SM, Elliott P, Karhunen V,
499 Giontella A, Fava C, Hellwege JN, Shuey MM, et al. Relationship Between Blood
500 Pressure and Incident Cardiovascular Disease: Linear and Nonlinear Mendelian
501 Randomization Analyses. *Hypertension*. 2021;77:2004–2013. doi:
502 10.1161/HYPERTENSIONAHA.120.16534.

- 503 27. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization
504 using the MR-Egger method. *Eur J Epidemiol.* 2017;32:377–389. doi:
505 10.1007/s10654-017-0255-x.
- 506 28. Bateman BT, Schumacher HC, Bushnell CD, Pile-Spellman J, Simpson LL,
507 Sacco RL, Berman MF. Intracerebral hemorrhage in pregnancy: frequency, risk
508 factors, and outcome. *Neurology.* 2006;67:424–429. doi:
509 10.1212/01.wnl.0000228277.84760.a2.
- 510 29. Hung S-K, Lee M-S, Lin H-Y, Chen L-C, Chuang C-J, Chew C-H, Yu B-H, Yang
511 H-J, Hsu F-C, Chiou W-Y. Impact of Hypertensive Disorders of Pregnancy on
512 the Risk of Stroke Stratified by Subtypes and Follow-Up Time. *Stroke.*
513 2022;53:338–344. doi: 10.1161/STROKEAHA.121.034109.
- 514 30. Auger N, Fraser WD, Schnitzer M, Leduc L, Healy-Profítós J, Paradis G.
515 Recurrent pre-eclampsia and subsequent cardiovascular risk. *Heart.*
516 2017;103:235–243. doi: 10.1136/heartjnl-2016-309671.
- 517 31. Robillard P-Y, Dekker G, Scioscia M. The necessity to specify paternities in all
518 obstetrical files in multigravidae. *J Reprod Immunol.* 2022;154:103747. doi:
519 10.1016/j.jri.2022.103747.
- 520 32. Peters SAE, Singhatheh Y, Mackay D, Huxley RR, Woodward M. Total
521 cholesterol as a risk factor for coronary heart disease and stroke in women
522 compared with men: A systematic review and meta-analysis. *Atherosclerosis.*
523 2016;248:123–131. doi: 10.1016/j.atherosclerosis.2016.03.016.
- 524 33. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood
525 AM, Lewington S, Sattar N, Packard CJ, et al. Major lipids, apolipoproteins, and
526 risk of vascular disease. *JAMA.* 2009;302:1993–2000. doi:
527 10.1001/jama.2009.1619.
528

529 **Figure Legends**

530 **Figure 1. Sex-specific Mendelian Randomisation analysis of genetically**
531 **proxied pre-eclampsia/eclampsia and risk of cardiovascular events.** Results are
532 from inverse variance weighted regression. Models were adjusted for age at baseline
533 and the first 16 genetic principal components. Abbreviations: CI, confidence interval;
534 CVD, cardiovascular disease; ICH, intracerebral haemorrhage; MI, myocardial
535 infarction; OR, odds ratio; SAH, subarachnoid haemorrhage.

536 **Figure 2. Sex-specific Mendelian Randomisation analysis of genetically**
537 **proxied gestational hypertension and risk of cardiovascular events.** Results are
538 from inverse variance weighted regression. Models were adjusted for age at baseline
539 and the first 16 genetic principal components. Abbreviations: CI, confidence interval;
540 CVD, cardiovascular disease; ICH, intracerebral haemorrhage; MI, myocardial
541 infarction; OR, odds ratio; SAH, subarachnoid haemorrhage.

542 **Figure 3. Sex-specific Mendelian Randomisation analysis of genetically**
543 **proxied pre-eclampsia/eclampsia and cardiovascular risk factors.** Results are
544 from inverse variance weighted regression. Results are from inverse variance
545 weighted regression. Models were adjusted for age at baseline and the first 16
546 genetic principal components. Abbreviations: ALAT, alanine aminotransferase;
547 ASAT, aspartate aminotransferase; CI, confidence interval; GGT, gamma
548 glutamyltransferase; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein;
549 LDL, low-density lipoprotein.

550 **Figure 4. Sex-specific Mendelian Randomisation analysis of genetically**
551 **proxied gestational hypertension and cardiovascular risk factors.** Results are
552 from inverse variance weighted regression. Models were adjusted for age at baseline
553 and the first 16 genetic principal components. Abbreviations: ALAT, alanine
554 aminotransferase; ASAT, aspartate aminotransferase; CI, confidence interval; GGT,
555 gamma glutamyltransferase; HbA1c, glycated hemoglobin; HDL, high-density
556 lipoprotein; LDL, low-density lipoprotein.

557

558 Tables

559 **Table 1. Participant characteristics.**

Characteristic	Overall (n=487,203)		Women (n=264,160)		Men (n=223,043)	
	N	Mean ± SD, median [IQR], N (%)	N	Mean ± SD, median [IQR], N (%)	N	Mean ± SD, median [IQR], N (%)
Age, years	487,203	56.5 ± 8.1	264,160	56.4 ± 8.0	223,043	56.7 ± 8.2
SBP, mmHg	460,029	137.8 ± 18.7	249,189	135.2 ± 19.2	210,840	140.9 ± 17.5
DBP, mmHg	460,034	82.2 ± 10.1	249,192	80.7 ± 10.0	210,842	84.1 ± 10.0
Hypertension	474,896	224,331 (47.2%)	264,054	117,037 (44.3%)	210,842	107,294 (50.9%)
Age at hypertension diagnosis, years	117,548	50.6 ± 9.9	54,552	50.0 ± 10.8	62,996	51.2 ± 9.1
Body mass index, kg/m ²	485,231	27.4 ± 4.8	263,213	27.1 ± 5.2	222,018	27.8 ± 4.2
Smoking status	484,701		262,851		221,850	
Never		265,322 (54.7%)		156,643 (59.6%)		108,679 (49.0%)
Ex		168,194 (34.7%)		82,760 (31.5%)		85,434 (38.5%)
Current		51,185 (10.6%)		23,448 (8.9%)		27,737 (12.5%)
Total cholesterol, mmol/L	464,313	5.7 ± 1.1	251,599	5.9 ± 1.1	212,714	5.5 ± 1.1
HDL cholesterol, mmol/L	424,993	1.4 ± 0.4	228,604	1.6 ± 0.4	196,389	1.3 ± 0.3
Triglycerides, mmol/L	463,945	1.5 [1.0, 2.1]	251,460	1.3 [1.0, 1.9]	212,485	1.7 [1.2, 2.4]
LDL cholesterol, mmol/L	463,446	3.6 ± 0.9	251,188	3.6 ± 0.9	212,258	3.5 ± 0.9
Lipoprotein(a), nmol/L	371,400	21.1 [9.6, 61.9]	201,844	22.2 [9.9, 62.0]	169,556	19.8 [9.2, 61.8]
Apolipoprotein A1, g/L	422,655	1.5 ± 0.3	226,557	1.6 ± 0.3	196,098	1.4 ± 0.2
Apolipoprotein B, g/L	461,972	1.0 ± 0.2	250,732	1.0 ± 0.2	211,240	1.0 ± 0.2
HbA1c, mmol/mol	462,868	36.1 ± 6.8	250,932	35.8 ± 6.0	211,936	36.5 ± 7.6
Creatinine, μmol/L	464,085	70.4 [61.4, 80.9]	251,489	63.1 [57.0, 70.0]	212,596	80.0 [72.5, 88.4]
Albumin, g/L	425,194	45.2 ± 2.6	228,687	44.9 ± 2.6	196,507	45.5 ± 2.6
ALAT, U/L	464,133	20.1 [15.4, 27.4]	251,592	17.5 [13.9, 22.9]	212,541	23.9 [18.4, 32.0]
ASAT, U/L	462,594	24.4 [21.0, 28.8]	250,727	23.0 [20.0, 26.8]	211,867	26.2 [22.6, 31.0]
Gamma-GT, U/L	464,074	26.3 [18.5, 41.0]	251,496	21.4 [16.1, 31.9]	212,578	33.1 [23.7, 50.3]
C-reactive protein, mg/L	463,305	1.3 [0.7, 2.8]	251,162	1.4 [0.6, 3.0]	212,143	1.3 [0.7, 2.5]

560

561

562

563

Abbreviations: ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; DBP, diastolic blood pressure; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase;; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation.







